健康男性68Ga-枸橼酸盐PET:全身生物分布动力学与辐射剂量估算
本研究在6名健康男性中行68Ga-枸橼酸盐全身PET/CT,评估其生物分布与辐射剂量。血液清除缓慢,尿液排泄 biologic 半衰期69±24小时,心肌壁吸收剂量最高(0.077±0.008 mSv/MBq),平均有效剂量0.021±0.001 mSv/MBq(ICRP 103)。作者认为200 MBq注射所致有效剂量4.2 mSv与其他68Ga标记示踪剂相当,提示临床研究可行且一年内可多次扫描。
要点
- 6名健康男性注射204±8 MBq 68Ga-枸橼酸盐后行全身PET/CT,血液放射性清除缓慢,3小时测量期内浓度较高。
- 尿液排泄较慢(生物学半衰期69±24小时),膀胱内容物衰减校正后最高浓度见于90和180分钟时间点。
- 心脏壁吸收剂量最高(0.077±0.008 mSv/MBq),平均有效剂量(ICRP 103)为0.021±0.001 mSv/MBq。
核心结论
- 68Ga-枸橼酸盐PET成像辐射暴露适中,200 MBq注射所致有效辐射剂量为4.2 mSv,与其他68Ga标记示踪剂处于相同范围。
- 作者认为这提示在人身上使用68Ga-枸橼酸盐成像开展临床研究的可行性,以及一年内对同一受试者进行多次扫描的可能性。
研究设计与样本
- 在6名健康男性(年龄41±12岁,均值±标准差)中开展序贯全身PET/CT扫描研究。
- 68Ga-枸橼酸盐采用基于丙酮的放射性标记程序制备,符合良好生产规范。
- 注射活度为204±8 MBq,PET成像期间采集系列动脉化静脉血样,用γ计数器测量放射性浓度,并收集尿液。
- 采用MIRD膀胱排尿模型(排尿间隔3.5小时),基于70 kg成年男性模型和MIRD体系估算靶器官吸收剂量与有效剂量,计算使用OLINDA/EXM软件2.0版。
主要发现
- 血液放射性清除缓慢,整个3小时测量期内观察到相对较高的放射性浓度。
- 尿液排泄较慢,生物学半衰期为69±24小时;膀胱内容物衰减校正后最高浓度见于90和180分钟时间点。
- 肾脏、肝脏和脾脏也可见中等浓度。
- 驻留时间最长的源器官为肌肉、肝脏、肺和心脏内容物。
- 心脏壁吸收剂量最高,为0.077±0.008 mSv/MBq;平均有效剂量(ICRP 103)为0.021±0.001 mSv/MBq。
关键数值与推荐
- 心脏壁吸收剂量0.077±0.008 mSv/MBq。
- 平均有效剂量(ICRP 103)0.021±0.001 mSv/MBq。
- 200 MBq注射68Ga-枸橼酸盐所致有效辐射剂量为4.2 mSv。
- 尿液排泄生物学半衰期69±24小时。
临床怎么用
- 作者认为68Ga-枸橼酸盐PET成像辐射暴露适中,提示临床研究可行,并可能一年内对同一受试者多次扫描。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-citrate has one of the simplest chemical structures of all 68Ga-radiopharmaceuticals, and its clinical use is justified by the proven medical applications using its isotope-labeled compound 67Ga-citrate. To support broader application of 68Ga-citrate in medical diagnosis, further research is needed to gain clinical data from healthy volunteers. In this work, we studied the biodistribution of 68Ga-citrate and subsequent radiation exposure from it in healthy men. Methods: 68Ga-citrate was prepared with an acetone-based radiolabeling procedure compliant with good manufacturing practices. Six healthy men (age 41 ± 12 y, mean ± SD) underwent sequential whole-body PET/CT scans after an injection of 204 ± 8 MBq of 68Ga-citrate. Serial arterialized venous blood samples were collected during PET imaging, and the radioactivity concentration was measured with a γ-counter. Urinary voids were collected and measured. The MIRD bladder-voiding model with a 3.5-h voiding interval was used. A model using a 70-kg adult man and the MIRD schema was used to estimate absorbed doses in target organs and effective doses. Calculations were performed using OLINDA/EXM software, version 2.0. Results: Radioactivity clearance from the blood was slow, and relatively high radioactivity concentrations were observed over the whole of the 3-h measuring period. Although radioactivity excretion via urine was rather slow (biologic half-time, 69 ± 24 h), the highest decay-corrected concentrations in urinary bladder contents were measured at the 90- and 180-min time points. Moderate concentrations were also seen in kidneys, liver, and spleen. The source organs showing the largest residence times were muscle, liver, lung, and heart contents. The heart wall received the highest absorbed dose, 0.077 ± 0.008 mSv/MBq. The mean effective dose (International Commission on Radiological Protection publication 103) was 0.021 ± 0.001 mSv/MBq. Conclusion: PET imaging with 68Ga-citrate is associated with modest radiation exposure. A 200-MBq injection of 68Ga-citrate results in an effective radiation dose of 4.2 mSv, which is in the same range as other 68Ga-labeled tracers. This suggests the feasibility of clinical studies using 68Ga-citrate imaging in humans and the possibility of performing multiple scans in the same subjects across the course of a year.
引用
- Suilamo S, Li XG, Lankinen P, et al. 68Ga-Citrate PET of Healthy Men: Whole-Body Biodistribution Kinetics and Radiation Dose Estimates. J Nucl Med. 2022. PMID: 35273093. doi:10.2967/jnumed.122.263884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。